ISU Abxis Co. Ltd (086890) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of ISU Abxis Co. Ltd KRW 727, price KRW 3,525, upside -79.4%, quality 18 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch ISU Abxis Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 2,975 KRW – 18,950 KRW · fair‑value band 702.13 KRW – 747.24 KRW · the 3,525 KRW price screens above the 727.12 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow ISU Abxis Co. in your weekly email
Every Wednesday you see whether ISU Abxis Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide.
Show more
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.
Stock analysis
ISU Abxis Co. Ltd (086890) currently trades at 3,525 KRW, while our model-based Fair Value estimate is 727.12 KRW, implying the stock looks roughly 384.7% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 1,933 KRW per share, and 0 of the 6 models we run sit above the 3,525 KRW price.
Bear case: the Earnings-Based group reads lowest at 867.45 KRW, and 6 of the 6 models stay below the price. Evidence for this calculation is low.
Scenario range: 702.13 KRW (bear) to 747.24 KRW (bull), the price of 3,525 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 18/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ISU Abxis Co. Ltd reported revenue of 56.7B KRW in FY2025 versus 28.0B KRW in FY2021, a compound +19.3%/yr. Reported net income was −10.7B KRW in FY2025.
Key figures
Market cap 140B KRW (≈ $103M) · P/S ratio 3.19 · Net margin −18.8% · Return on equity 2,806% · Return on assets (EBIT) −3.9% · Operating margin −22.1% · Revenue (TTM) 39.6B KRW · Revenue growth (YoY) +86.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 44% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −41% fair-value upside, at −79%, 086890 screens richer than that median.
Fair Value models
Bear 702.13 KRWFair Value 727.12 KRWBull 747.24 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.2%
Start year 2020 (pandemic). Over 10 years: +17.3% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.8%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−51.5% (2020) → 2.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 55 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score18 · Bottom 25%
Fair Value upside−79% · Bottom 25%
Profitability
Return on assets−4% · Bottom 25%
Net margin (TTM)1% · Below median
Operating margin (TTM)−22% · Bottom 25%
Growth and dividend
Revenue growth86% · Top 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 28
FUTURE (revenue growth)100· sector 63
PAST (return on equity)0· sector 10
HEALTH (low debt)100· sector 98
DIVIDEND (yield)0· sector 29
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is ISU Abxis Co. Ltd (086890) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 727.12 KRW versus a price of 3,525 KRW, about −79% upside (overvalued).
What is the fair value of 086890?
Our model-based fair value for ISU Abxis Co. Ltd is 727.12 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,525 KRW.
What is the quality score of 086890?
ISU Abxis Co. Ltd has a Quality Score of 18/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for ISU Abxis Co. Ltd (086890)?
Our model-based price target is the fair value of 727.12 KRW (as of Sep 24, 2026) from 6 valuation models. Cautious scenario 702.13 KRW, optimistic scenario 747.24 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the ISU Abxis Co. Ltd stock forecast for 2026?
Our models put fair value at 727.12 KRW, about −79% upside versus a price of 3,525 KRW (overvalued). Cautious scenario 702.13 KRW, optimistic scenario 747.24 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of ISU Abxis Co. Ltd (086890)?
ISU Abxis Co. Ltd reported trailing-twelve-month revenue of about 39.6B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of ISU Abxis Co. Ltd (086890)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For ISU Abxis Co. Ltd it is 727.12 KRW per share (as of Sep 24, 2026), against a price of 3,525 KRW. It is the blended result of 6 valuation models (cash flow, earnings, asset, dividend).
Is ISU Abxis Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 086890 trades above its calculated fair value: price 3,525 KRW, fair value 727.12 KRW, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 086890?
No. The price is what the market pays today (3,525 KRW); the fair value is what the company's own numbers justify (727.12 KRW). For ISU Abxis Co. Ltd the two are 2,798 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is ISU Abxis Co. Ltd worth?
The market values ISU Abxis Co. Ltd at about 140B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,525 KRW; our models calculate a fair value of 727.12 KRW per share.
What do the bullish and bearish scenarios say about 086890?
Our models span a range for ISU Abxis Co. Ltd: cautious scenario 702.13 KRW, base 727.12 KRW, optimistic 747.24 KRW per share (as of Sep 24, 2026, price 3,525 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 086890 from its 52-week high?
ISU Abxis Co. Ltd trades at 3,525 KRW, about 44% below its 52-week high of 6,240 KRW and 18% above the low of 2,975 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 727.12 KRW is for.
Which stocks are comparable to ISU Abxis Co. Ltd?
From the same area (Healthcare) we also value Caregen Co, ST Pharm Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is ISU Abxis Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 3,525 KRW, calculated fair value 727.12 KRW (−79%), Quality Score 18/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 086890 calculated?
We run ISU Abxis Co. Ltd through 6 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 727.12 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. ISU Abxis Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of ISU Abxis Co. Ltd (086890)?
The closing price on Sep 23, 2026 was 3,525 KRW. Our model-based fair value is 727.12 KRW, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with ISU Abxis Co. Ltd right now?
The price sits above even our optimistic bull case (747.24 KRW). The favourable scenario is already priced in. Weak quality (18/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (702.13 KRW to 747.24 KRW), unusually little disagreement for a valuation.
Key figures of ISU Abxis Co. Ltd
How large is the market capitalisation of ISU Abxis Co. Ltd (086890)?
The market capitalisation of ISU Abxis Co. Ltd is 140B KRW (≈ $103M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of ISU Abxis Co. Ltd (086890)?
The price-to-sales ratio of ISU Abxis Co. Ltd is 3.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of ISU Abxis Co. Ltd (086890)?
The net margin of ISU Abxis Co. Ltd is −18.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of ISU Abxis Co. Ltd (086890)?
The return on equity (ROE) of ISU Abxis Co. Ltd is 2,806% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of ISU Abxis Co. Ltd (086890)?
On an EBIT basis the return on assets of ISU Abxis Co. Ltd is −3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of ISU Abxis Co. Ltd (086890)?
The operating margin of ISU Abxis Co. Ltd is −22.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at ISU Abxis Co. Ltd (086890)?
Revenue at ISU Abxis Co. Ltd is growing +86.4% versus a year earlier (3y avg +11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does ISU Abxis Co. Ltd (086890) generate?
The free cash flow of ISU Abxis Co. Ltd is −89.7M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does ISU Abxis Co. Ltd (086890) carry?
The net debt of ISU Abxis Co. Ltd is 4.5B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch ISU Abxis Co. Ltd in the live analysis
One click puts ISU Abxis Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
